Icagen
5
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
40.0%
2 terminated/withdrawn out of 5 trials
60.0%
-26.5% vs industry average
40%
2 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
Role: lead
Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma
Role: lead
Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects
Role: lead
A Stratified Sickle Event Randomized Trial (ASSERT)
Role: lead
A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
Role: lead
All 5 trials loaded